Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

Abstract: Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.

Keywords: non-small cell lung cancer, MET, hepatocyte growth factor, ficlatuzumab, AV-299

Introduction

Lung cancer is a big killer in oncology, accounting for 1.3 million deaths per year worldwide.1 This disease includes two major histologic categories: small-cell lung cancer (SCLC, 15%–20% of cases) and non-small cell lung cancer (NSCLC, 80%–85% of cases) including adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Beyond histologic aspects, lung cancer differs by the molecular aberration at the base of its pathogenesis and sustenance. Several oncogenic alterations in the genetic code and protein expression have so far been identified as conceivable targets for treatment. These molecular aberrations define subsets of patients with specific prognosis and outcome following treatment. Epidermal growth factor receptor (EGFR) gene mutations can be detected in 10%–15% of Caucasians and in up to 40% of Asian NSCLC patients. Soon after their discovery in 2004, they were recognized as the principal biomarker in lung adenocarcinoma predicting response to treatment with the EGFR tyrosine kinase inhibitors (TKI).2 Seven phase III trials including thousands of patients treated with gefitinib, erlotinib, or afatinib, clearly demonstrated that EGFR TKI are the best option as first-line therapy for EGFR mutated NSCLC.3–9 Disease control can be reached in up to 90% of mutant individuals, but none of them can be definitively cured and progression of disease inevitably occurs. Moreover, a consistent proportion of patients show primary resistance to EGFR inhibitors, even in the presence of EGFR activating mutations. Resistance is usually determined by secondary genomic alterations in the target kinase altering the physical or biochemical properties of the receptor and by the
activation of collateral pathways. In 50% of cases a secondary gatekeeper mutation in the EGFR gene (T790M, D761Y) is responsible for acquired resistance. An additional 20% of refractory patients harbor overexpression of another tyrosine kinase receptor, the mesenchymal–epithelial transition (MET) receptor, which allows inhibition of the EGFR pathway to be bypassed. Some preclinical studies described a correlation between EGFR TKI resistance and overexpression of the c-MET ligand, hepatocyte growth factor (HGF). Several strategies to overcome resistance to EGFR TKI are being explored in preclinical and clinical trials. In case of a secondary mutation, irreversible TKI, heat shock protein 90 inhibitors, or combined treatment with anti-EGFR antibodies are under evaluation. Several MET inhibitors have so far been developed including monoclonal antibodies (ornatuzumab) and small molecule inhibitors (crizotinib, foretinib, cabozaantinib, GCD265, tivantinib). Another possible strategy under evaluation is the blockade of HGF by competitive antagonists (NK4) or specific antibodies (AMG102/rilotumumab, AV-299/ficlatuzumab). In this review we will describe the c-MET/hHGF signaling pathway in NSCLC, HGF expression as a resistance mechanism to EGFR TKI, and the possible role of HGF inhibition in the treatment of lung cancer patients, focusing specifically on ficlatuzumab.

**c-MET/hHGF axis and lung cancer**

The c-MET oncogene was first identified in the mid 1980s. It encodes a member of the receptor tyrosine kinase family and is structurally distinct from other components of the family. The receptor is a heterodimer composed of two subunits, the α- and β-chain (Figure 1). The α-chain is completely extracellular and is linked to the β-chain by a disulphide bond. The β-chain includes three domains: an extracellular portion, a transmembrane domain, and a cytoplasmic one. The intracellular domain contains a juxtamembrane portion, a tyrosine kinase domain, and a carboxy-terminal tail.

Shortly after the discovery of MET, its physiological ligand, HGF or scatter factor, was identified. It is a platelet-derived mitogen for hepatocytes and other normal cell types and a fibroblast-derived factor for epithelial cell scattering, ie, it induces random movement in epithelial cells. HGF is a morphogen that induces transition of epithelial cells into a mesenchymal morphology. Both tumor and stromal cells have been identified as potential sources of HGF. Co-culture studies investigating tumor–stromal interaction demonstrated that fibroblast-dependent carcinoma cell growth and invasion is inhibited by anti-HGF antibodies, highlighting the importance of stroma-derived HGF in tumor sustenance and progression.

**Figure 1** c-MET/HGF pathway.

**Abbreviations:** HGF, hepatocyte growth factor; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; Gab1, GRB-associated binding protein 1; STAT3, signal transducer and activator of transcription 3; SRC, sarcoma; Grb2, growth factor receptor-bound protein 2; SOS, son of sevenless; FAK, focal adhesion kinase-1; Pxn, paxillin; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; MEK 1/2, MAPK/ERK kinase; ERK, extracellular signal regulated kinase.
It is synthesized in an inactive form and then converted into a two-chain heterodimer, including an amino-terminal domain (N), four Kringle domains (K1–K4), and a serine protease homology domain. The N-K1 portion is responsible for MET binding and dimerization or multimerization. The joining of two or more c-MET receptors leads to phosphorylation of the tyrosine residues Y1234 and Y1235 in the tyrosine kinase domain, and phosphorylation of the residues Y1349 and Y1356 near the carboxy-terminal tail. The phosphorylation of the carboxy-terminal tail forms a multifunctional docking site that recruits intracellular adapters and substrates such as STAT3, Grb2, Gab1, PI3K, Shc, Src, Shp2, and Shp1. Thus, several pathways involved in proliferation, survival, cell motility, invasion, and metastasis are activated. Interestingly, c-MET activation leads to the recruitment of effectors involved in the epithelial–mesenchymal transition through RAS/MAPK signaling and the FAK/paxillin complex (Figure 1).

Deregulation of c-MET/HGF signaling may result in carcinogenesis in several solid tumors. The most common mechanism of activation is c-MET protein expression due to transcriptional upregulation in the absence of gene amplification. Receptor overexpression can also be determined by gene amplification. Another rare mechanism of activation of the axis is by mutation of the c-MET gene. Kinase activation may be ligand independent, but in cancer it is mainly caused by binding of the ligand. Even in the case of c-MET activating mutations, HGF is needed to start the catalytic activity of the receptor. HGF plays a fundamental role in the c-MET axis in cancer as it can act either as a paracrine factor, causing positive feedback leading to c-MET transcription, or act by an autocrine mechanism.

c-MET gene amplification and overexpression have been associated with poor patient outcome in several studies. The concentration of HGF in serum or cancer tissue was associated with progression of disease in many cancer types including breast, gastric, bladder, colorectal, SCLC, and myeloma. Several studies on NSCLC reported intratumoral and plasma HGF levels to be prognostic indicators. Two research groups analyzed the intratumoral levels of HGF in 56 and 183 resected NSCLC respectively and found an inverse correlation between HGF levels and overall survival, i.e., individuals with high levels of intratumoral HGF were likely to have a worse prognosis. More recently, Hosoda et al studied plasma HGF levels in 25 resected NSCLC, revealing a better outcome in terms of both disease free survival (P = 0.032) and overall survival (P = 0.020) for patients with lower levels of HGF. In a similar study by Ujiie et al, HGF plasma levels were a negative prognostic factor only for survival (P = 0.016) in a cohort of 109 surgically treated NSCLC patients.

**Role of HGF in EGFR TKI resistance and rationale for its blockade**

Other than a prognostic indicator, HGF seems to be involved in resistance to agents targeting the EGFR family, not only in lung cancer but also in other malignancies. Recently, our group investigated the role of MET and HGF gene copy number in a large population of metastatic breast cancer patients treated with trastuzumab, an anti-HER2 antibody, and we showed that high MET and HGF gene copy numbers associated with an increased risk of resistance to the anti-HER2 therapy. In lung cancer, HGF can independently activate both PI3K/AKT and ERK signaling leading to drug resistance in the presence of EGFR TKI. Unlike MET amplified resistant cancers, HGF-mediated resistance occurs through Gab1 and does not involve HER3. In 2008, a Japanese group administered HGF to an adenocarcinoma cell line harboring a sensitizing EGFR gene exon 19 deletion and found that HGF induced resistance in a dose-dependent manner. Higher levels of HGF can be detected in tumor specimens from NSCLC patients that are clinically resistant to gefitinib or erlotinib compared to pretreatment tumor specimens. Yano et al analyzed HGF expression in paraffin-embedded specimens from 93 EGFR mutant lung cancer patients and found a higher level of HGF expression in tumors with intrinsic and acquired resistance to EGFR TKI. In another study, Turke et al compared HGF levels in 16 NSCLC patients for which pre- and post-treatment specimens were available and found that HGF expression was significantly higher in the TKI resistant specimens than in the pretreatment specimens, supporting a role for HGF alone in promoting drug resistance. Both these research groups postulated that HGF may induce EGFR TKI resistance by selection of clones with MET gene amplification. Recently some researchers investigated whether HGF levels in blood may predict response to EGFR TKI treatment. Several studies analyzed HGF levels in serum from NSCLC patients treated with an EGFR TKI and not selected according to their EGFR mutational status, finding a strong correlation between serum HGF levels and outcome of treatment.
Moreover, HGF can convert cancer cells from an epithelial to a mesenchymal phenotype and it is known that lung cancers expressing mesenchymal markers are more resistant to EGFR TKI treatment than tumors with an epithelial phenotype. A prominent question for all resistance mechanisms is whether they occur as a consequence of treatment or if they exist prior to treatment and are selected under therapy pressure. Growing evidence indicates that resistance mechanisms are already present in small clones of tumor cells, as in the case of secondary EGFR mutations and MET amplification. Therefore, treatment with a combination of an EGFR TKI and an anti-HGF or anti-MET agent, particularly in patients with evidence of MET amplification or HGF overexpression, could be more effective than an EGFR TKI alone. In addition, HGF and its receptor are clearly involved in the processes of invasion and metastasis and preclinical data suggest a synergistic effect of EGFR TKI and anti-MET agents, even in EGFR wild-type models. For all the listed reasons, anti-MET and anti-HGF strategies are currently under development in NSCLC and other malignancies.

Preclinical data suggested that HGF inhibition could be potentially effective against lung cancer. Okamoto et al examined the effects of adding an anti-HGF antibody (TAK-701) to gefitinib treatment in an EGFR mutant cell line engineered to stably express HGF. The combination suppressed cell growth by inhibition of phosphorylation of MET and of the downstream effectors of the EGFR pathway (EGFR, ERK, and AKT), indicating that autocrine c-MET/HGF signaling contributes to gefitinib resistance. In athymic nude mice, the combination therapy of TAK-701 and gefitinib inhibited tumor growth in vivo. In another study, a different anti-HGF antibody (L2G7) was used in combination with gefitinib in HGF expressing mice in which lung tumors were induced by exposure to a carcinogen. The mean tumor number in the group treated with the combination of L2G7 and gefitinib was significantly lower than with single agents. Apoptosis was significantly higher in the group treated with combination therapy (17-fold) compared to a single agent (7.9- and 3.5-fold for L2G7 and gefitinib, respectively).

Ficlatuzumab: current status and future directions

Ficlatuzumab (SCH 900105 or AV-299, Aveo Pharmaceuticals, Inc, Cambridge, MA, USA) is a humanized IgG1 antibody that binds the HGF ligand with high affinity and specificity, thus inhibiting c-MET/HGF biological activities. Its pharmacokinetic profile is characterized by a dose-proportional drug exposure with a low systemic clearance and a terminal half-life of 7–10 days. In a phase I trial, ficlatuzumab monotherapy resulted in decreases of phospho-MET, phospho-ERK, phospho-AKT, and Ki67. The anti-tumor efficacy of ficlatuzumab was evaluated in paracrine models of a HGF-dependent NSCLC cell line xenografted into SCID mice engineered to produce human HGF. Ficlatuzumab monotherapy decreased tumor growth in a dose-dependent manner and led to significant reductions in phospho-c-MET and phospho-AKT levels, but produced a concurrent increase in phospho-EGFR levels. Therefore, ficlatuzumab was studied in combination with erlotinib or cetuximab, and the two combination treatments showed increased antitumor activity when compared to the single agents. The potent antitumor activity of the combination with EGFR inhibitors observed in preclinical models supported further development in NSCLC patients. In a phase I trial, ficlatuzumab was administered both as a single agent (in 24 patients) and in combination with erlotinib 150 mg daily (in 13 patients) in 37 patients with solid tumors, and was well tolerated up to the maximum tested dose of 20 mg/kg every two weeks. The most common toxicities of ficlatuzumab monotherapy were fatigue, peripheral edema, headache, and diarrhea; skin rash and diarrhea were the major side effects of the combination treatment. Another phase Ib trial studied ficlatuzumab in association with gefitinib in 15 molecularly unselected Asian NSCLC patients. The recommended phase II dose was 20 mg/kg every two weeks for ficlatuzumab and 250 mg daily for gefitinib. Among the twelve patients treated in the 20 mg/kg arm, five were EGFR TKI naïve and all of them reached a partial response. In the same treatment arm, stabilization of disease was observed in four cases and progression in three cases.

Recently, Mok et al presented the results of a randomized phase II trial comparing gefitinib as single agent versus the combination of gefitinib and ficlatuzumab. The study enrolled 188 Asian treatment naïve patients with lung adenocarcinoma not selected for EGFR mutational status, even if the study population had clinical characteristics frequently associated with the presence of EGFR mutations. The primary endpoint of the study was to compare the overall response rate between treatment arms. In the overall population there was no statistical difference in response rate (40% for gefitinib arm versus 43% for the combination arm) or progression free survival (4.7 months versus 5.6 months in the gefitinib arm versus combination arm, respectively). Surprisingly, subgroup analyses showed that combination therapy was more effective in patients with low MET expression. In particular, patients with activating mutations in the EGFR gene and low c-MET levels seemed to benefit more from the combination in terms of progression free survival,
indicating that c-MET/HGF inhibition may delay the rise of EGFR TKI resistance in this specific population of lung cancer patients. Nevertheless, the low number of patients included in the subgroup analyses precludes any firm conclusion.

The phase II trial with ficlatuzumab did not reach its primary endpoint but its exploratory biomarker analysis provided important directions for future studies with this agent. In our opinion, anti-MET agents should be explored mainly in three groups of NSCLC patients (Figure 2): (1) In EGFR TKI naive patients harboring EGFR mutations in combination with EGFR TKI. Because MET amplification is one of the most relevant mechanisms involved in EGFR TKI resistance,\(^{11,74}\) it is possible that combining an EGFR TKI with an anti-MET agent leads to a delay in tumor progression; (2) In EGFR wild-type patients with high MET expression or MET gene amplification. MET gene amplification is a rare event in NSCLC, occurring in approximately 5% of cases.\(^{75}\) Data with onartuzumab, another anti-MET antibody, suggested that this agent in combination with erlotinib is more effective than an anti-MET agent alone in NSCLC cell lines with acquired resistance to reversible EGFR TKI.\(^{12}\) Moreover, we observed that high levels of MET amplification, known to be associated with gefitinib resistance in vitro, rarely occurs in untreated NSCLC, irrespective of EGFR status, and that it may develop only under therapeutic pressure, leading to the conclusion that, in EGFR TKI naïve patients, the level of genomic gain for MET is not increased enough to impact response to TKI. This finding has clinical implications since support for anti-MET strategies should be focused particularly on EGFR TKI resistant patients, where MET gene gain is more frequently observed and can drive tumor resistance.\(^{75}\)

**Conclusion**

The treatment of advanced NSCLC has deeply changed during the last decade and is rapidly moving toward personalized medicine. Biomarker analysis is becoming more and more important for defining prognosis and for offering the best treatment to our patients. c-MET and HGF have emerged as important biomarkers in NSCLC and other malignancies. Ficlatuzumab is a monoclonal antibody directed against HGF with promising preclinical activity; so far it has not been confirmed in clinical trials. To date, only data from a phase II trial are available and additional studies are planned. Nevertheless, accurate patient selection is of crucial relevance for understanding the real benefit produced by the drug and for offering our patients new therapies positively impacting on survival.

**Acknowledgment**

In part supported by the Italian Association for Cancer Research (AIRC) and Associazione Oncologia Traslazionale (AOT).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


70. Elez E, Taberner J, Prudkin L, et al. Pharmacodynamic (PD) – pharmacokinetic (PK) study of ficlatuzumab (F), a monoclonal antibody (MAB) directed to the hepatocyte growth factor (HGF), in patients (Ps) with advanced solid tumors who have live metastases (Mets). *Ann Oncol.* 2012;23(Suppl 9):ix154; Abstract 443PD.


73. Mok TSK, Park K, Geater SL, et al. A randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (Pts) with lung adenocarcinoma (LA). *Ann Oncol.* 2012;23(Suppl 9):ix391; Abstract 1198P.

